Merck and Moderna maintain a decade-old 50/50 collaboration on the personalized mRNA cancer vaccine intismeran, recently bolstered by positive Phase 3 melanoma data that drove Moderna's shares sharply higher in August 2026 without any signals of deeper structural integration. Merck has instead pursued targeted acquisitions such as Terns Pharmaceuticals to bolster its hematology pipeline amid Keytruda exclusivity pressures, while its scale and focus on established commercial assets contrast with Moderna's biotech profile and manufacturing emphasis. Trader consensus at 98.9% against a 2026 announcement reflects the absence of regulatory filings, leaked discussions, or comparable mega-deal precedents in the sector. Tail risks remain limited to abrupt strategic pivots from patent cliffs or competitive threats that could force consolidation.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоMerck & Moderna merger/acquisition announced in 2026?
Merck & Moderna merger/acquisition announced in 2026?
1% шанс
НОВЕ
НОВЕ
Dec 31, 2026
1% шанс
НОВЕ
НОВЕ
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old 50/50 collaboration on the personalized mRNA cancer vaccine intismeran, recently bolstered by positive Phase 3 melanoma data that drove Moderna's shares sharply higher in August 2026 without any signals of deeper structural integration. Merck has instead pursued targeted acquisitions such as Terns Pharmaceuticals to bolster its hematology pipeline amid Keytruda exclusivity pressures, while its scale and focus on established commercial assets contrast with Moderna's biotech profile and manufacturing emphasis. Trader consensus at 98.9% against a 2026 announcement reflects the absence of regulatory filings, leaked discussions, or comparable mega-deal precedents in the sector. Tail risks remain limited to abrupt strategic pivots from patent cliffs or competitive threats that could force consolidation.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Ринок відкрито: Aug 19, 2026, 3:58 PM ET
Обсяг
$425Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-old 50/50 collaboration on the personalized mRNA cancer vaccine intismeran, recently bolstered by positive Phase 3 melanoma data that drove Moderna's shares sharply higher in August 2026 without any signals of deeper structural integration. Merck has instead pursued targeted acquisitions such as Terns Pharmaceuticals to bolster its hematology pipeline amid Keytruda exclusivity pressures, while its scale and focus on established commercial assets contrast with Moderna's biotech profile and manufacturing emphasis. Trader consensus at 98.9% against a 2026 announcement reflects the absence of regulatory filings, leaked discussions, or comparable mega-deal precedents in the sector. Tail risks remain limited to abrupt strategic pivots from patent cliffs or competitive threats that could force consolidation.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Обсяг
$425Дата завершення
Jan 1, 2027Ринок відкрито
Aug 19, 2026, 3:58 PM ETВирішувач
0x65070BE91...Merck and Moderna maintain a decade-old 50/50 collaboration on the personalized mRNA cancer vaccine intismeran, recently bolstered by positive Phase 3 melanoma data that drove Moderna's shares sharply higher in August 2026 without any signals of deeper structural integration. Merck has instead pursued targeted acquisitions such as Terns Pharmaceuticals to bolster its hematology pipeline amid Keytruda exclusivity pressures, while its scale and focus on established commercial assets contrast with Moderna's biotech profile and manufacturing emphasis. Trader consensus at 98.9% against a 2026 announcement reflects the absence of regulatory filings, leaked discussions, or comparable mega-deal precedents in the sector. Tail risks remain limited to abrupt strategic pivots from patent cliffs or competitive threats that could force consolidation.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання